Weekly BI 836880 in Patients With Advanced Solid Tumors

NCT02689505 | Completed Phase 1 Results

• 2 other identifiers: 1336.62015-001132-38
• Study Type: interventional
• Target: 24
• Locations: 2 countries
• Sites: 2

Brief Summary

This is a Phase I, multi-centre, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously once a week. The eligible patient population will be patients with advanced solid tumors. The primary objective of this trial is to determine the maximum tolerated dose (MTD) and recommended Phase II doses for BI 836880 in patients with solid tumors. Preliminary safety data will be evaluated as secondary objectives. Subsequently, pharmacokinetic profile, pharmacodynamic changes in circulating biomarkers and Dynamic Contrast-Enhanced Magnetic Resonance Imaging ( DCE-MRI), anti-tumor activity and the immunogenicity of BI 836880 will be explored up to a total of 40 patients with advanced solid tumors. Dose escalation will be guided by a Bayesian logistic regression model with over dose control (EWOC) using at least 2 patients per dose cohorts. Safety criteria will be followed, including adverse events according to Common Terminology Criteria (CTCAE version 4.03), incidence of dose limiting toxicities, physical examination, vital signs, safety laboratory parameters and Eastern Cooperative Oncology Group (ECOG).

Conditions

Neoplasms

Outcome Measures

Primary Outcomes (2)

• Maximum Tolerated Dose (MTD)

  Determination of the maximum tolerated dose (MTD) in participants with advanced solid tumors. MTD was defined as the highest dose with less than 25% risk of true DLT rate being above 33% in the MTD evaluation period, and could be considered reached if the probability that the true DLT rate was in the target interval (16% to 33%) was sufficiently large during the MTD evaluation period. The MTD evaluation period was defined as 3 weeks after first administration of treatment.

  First treatment cycle, 3 weeks from first administration of trial treatment (MTD evaluation period).

• Number of Participants With Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) Evaluation Period

  The following drug-related adverse events qualified as DLTs: Common Terminology Criteria for Adverse Events (CTCAE) grade 4 neutropenia \>7 days or complicated by infection; grade \>3 febrile neutropenia; grade = 4 thrombocytopenia; grade \> 3 thrombocytopenia with bleeding; grade \> 3 proteinuria \> 3 non haematological toxicity except: Vomiting or diarrhea responding to supporting treatment, fatigue lasting for less than 4 days, transient grade 3 infusion reaction, any laboratory abnormality, which was considered not clinically relevant by the investigator or resolved spontaneously or could be resolved with appropriate treatment. Hypertension: increase of diastolic blood pressure (BP) by 15 mmHg, which could not be controlled by hypertensive medication and requires a dose reduction of BI 836880 for further treatment course. All related AE leading to an interruption of BI 836880 for more than 14 days until recovery to baseline.

  First treatment cycle, 3 weeks from first administration of trial treatment (MTD evaluation period).

Secondary Outcomes (1)

• Number of Participants With Drug-related Adverse Events (AEs) Leading to Dose Reduction or Discontinuation During the Treatment Period

  From first trial drug administration until 42 (Residual Effect Period) days after the last trial drug administration, up to 566 days.

Study Arms (5)

40 mg BI 836880

EXPERIMENTAL

40 mg BI 836880

Drug: BI 836880

120 mg BI 836880

EXPERIMENTAL

120 mg BI 836880

Drug: BI 836880

150 mg BI 836880

EXPERIMENTAL

150 mg BI 836880

Drug: BI 836880

180 mg BI 836880

EXPERIMENTAL

180 mg BI 836880

Drug: BI 836880

240 mg BI 836880

EXPERIMENTAL

240 mg BI 836880

Drug: BI 836880

Interventions

BI 836880 DRUG

Solution for intravenous infusion

120 mg BI 836880; 150 mg BI 836880; 180 mg BI 836880; 240 mg BI 836880; 40 mg BI 836880

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>=18 years 2. Histologically confirmed malignancy which is locally advanced or metastatic solid tumor, and either refractory after standard therapy for the disease or for which standard therapy is not reliably effective e.g. patients do not tolerate or have contraindications to otherwise available standard therapy and tumour lesions evaluable for Dynamic contrast-enhanced (DCE)-MRI at MTD.
• \. ECOG performance status \<= 2 4. Adequate hepatic, renal and bone marrow functions as defined by the following criteria:
• Total bilirubin within normal limits (\<= 1.5x upper limit of normal (ULN) for patient with Gilberts syndrome)
• Alanine amino transferase (ALT) and aspartate amino transferase (AST) \<= 1.5x ULN (\< 5x upper limit of normal (ULN) for patient known liver metastases)
• Serum creatinine \< 1.5x ULN
• International normalized Ratio (INR) 0.8-1.2 or partial thromboplastin time (PTT) \< 1.5x ULN
• Absolute neutrophil count (ANC) \> 1.5 109/L
• Platelet count \> 100x109/ L.
• Haemoglobin \> 10 g/dl (without transfusion within previous week) 5. Signed and dated written informed consent. 6. Life expectancy \>= 3 months in the opinion of the investigator 7. Recovery from all reversible adverse events of previous anti-cancer therapies to baseline or CTCAE grade1, except for alopecia (any grade), sensory peripheral neuropathy CTCAE grade \<= 2 or considered by the investigator as clinically not significant.
• \. Male or female patients. Women of childbearing potential\* must be ready and able to use highly effective methods of birth control per International Conference on Harmonisation \[ICH M3(R2)\] in combination with male condom as "double barrier", during the trial and for at least 6 months after the end of treatment with BI 836880, that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
• Male patient must always use condoms when sexually active during the trial and for at least 6 months after the end of treatment with BI 836880.
• \*Women of childbearing potential are defined as: Any female who has experienced menarche and does not meet the criteria for "women not of childbearing potential" as described below.
• Women not of childbearing potential are defined as:
• Women who are postmenopausal (12 months with no menses without an alternative medical cause) or who are permanently sterilized (e.g., hysterectomy, bilateral oophorectomy or bilateral salpingectomy).

You may not qualify if:

• Known hypersensitivity to the trial drugs or their excipients or risk of allergic of anaphylactic reaction to the study drug according to the investigator judgement (e.g. patient with history of anaphylactic reaction or autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDS), inhaled corticosteroids, or the equivalent of \< 10 mg/day prednisone)
• Current or prior treatment with any systemic anti-cancer therapy either within 28 days or a minimum of 5 half-lives, whichever is shorter at the start of study treatment.
• Serious concomitant disease (based on investigator judgement), especially those affecting compliance with trial requirements or which are considered relevant for the evaluation of the endpoints of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
• Major injuries and/or surgery (as judged by the investigator) or bone fracture within 4 weeks of start of study treatment, or planned surgical procedures during the trial period.
• Patients with personal or family history of QT prolongation and/or long QT syndrome, or prolonged QT interval corrected for heart rate according to Fridericia's formula (QTcF) at baseline (\> 470 ms). QTcF will be calculated by Investigator as the mean of the 3 ECGs taken at screening.
• Significant cardiovascular/ cerebrovascular disease (i.e uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure \> New York heart association ( NYHA II). Uncontrolled hypertension defined as: blood pressure in tested and relaxed condition \>= 140 mmHg, systolic or \> 90 mmHg diastolic (with or without medication), measured according to Section 5.3.2 and Appendix 10.2.
• History of severe haemorrhagic or thromboembolic event in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).
• Known inherited predisposition to bleeding or to thrombosis in the opinion of the investigator.
• Patient with brain metastases that are symptomatic and/or require therapy.
• Patients who require full-dose anticoagulation (according to local guidelines). No vitamin K antagonist and other anticoagulation allowed; low-molecular-weight heparin (LMWH) allowed only for prevention not for curative treatment.
• Use of alcohol or drug incompatible with patient participation in the study in the investigator opinion
• Patient unable or unwilling to comply with protocol
• Women who are pregnant, nursing, or who plan to become pregnant while in the trial
• Previous enrolment in this trial

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Sites (2)

CTR Georges-François Leclerc

Dijon, 21079, France

Location

Hospital Vall d'Hebron

Barcelona, 08035, Spain

Location

Related Publications (2)

• Keller S, Kunz U, Schmid U, Beusmans J, Buchert M, He M, Jayadeva G, Le Tourneau C, Luedtke D, Niessen HG, Oum'hamed Z, Pleiner S, Wang X, Graeser R. Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor. J Transl Med. 2024 Oct 14;22(1):934. doi: 10.1186/s12967-024-05612-x.

  PMID: 39402675 DERIVED

• Le Tourneau C, Becker H, Claus R, Elez E, Ricci F, Fritsch R, Silber Y, Hennequin A, Tabernero J, Jayadeva G, Luedtke D, He M, Isambert N. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open. 2022 Oct;7(5):100576. doi: 10.1016/j.esmoop.2022.100576. Epub 2022 Sep 13.

  PMID: 36108560 DERIVED

MeSH Terms

Conditions

Neoplasms

Results Point of Contact

• Title: Boehringer Ingelheim, Call Centre
• Organization: Boehringer Ingelheim

clintriage.rdg@boehringer-ingelheim.com

1-800-243-0127

Study Officials

• Boehringer Ingelheim

  Boehringer Ingelheim

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 23, 2016
• First Posted: February 24, 2016
• Study Start: April 4, 2016
• Primary Completion: July 31, 2019
• Study Completion: July 31, 2019
• Last Updated: October 1, 2025
• Results First Posted: October 1, 2025

Record last verified: 2025-09

Locations

ES (1); FR (1)